×
S&P 500   3,931.65 (-0.25%)
DOW   31,798.94 (-0.41%)
QQQ   285.53 (-0.60%)
AAPL   138.43 (-1.38%)
MSFT   258.50 (-0.43%)
FB   180.16 (-0.62%)
GOOGL   2,102.46 (-0.80%)
AMZN   2,071.00 (-0.53%)
TSLA   620.57 (-1.21%)
NVDA   159.72 (-1.13%)
BABA   83.16 (+0.84%)
AMD   90.38 (-0.86%)
MU   66.03 (-0.89%)
T   21.15 (-0.05%)
F   12.36 (-0.48%)
PFE   53.17 (-0.45%)
PYPL   77.92 (-0.93%)
NFLX   179.16 (-0.65%)
S&P 500   3,931.65 (-0.25%)
DOW   31,798.94 (-0.41%)
QQQ   285.53 (-0.60%)
AAPL   138.43 (-1.38%)
MSFT   258.50 (-0.43%)
FB   180.16 (-0.62%)
GOOGL   2,102.46 (-0.80%)
AMZN   2,071.00 (-0.53%)
TSLA   620.57 (-1.21%)
NVDA   159.72 (-1.13%)
BABA   83.16 (+0.84%)
AMD   90.38 (-0.86%)
MU   66.03 (-0.89%)
T   21.15 (-0.05%)
F   12.36 (-0.48%)
PFE   53.17 (-0.45%)
PYPL   77.92 (-0.93%)
NFLX   179.16 (-0.65%)
S&P 500   3,931.65 (-0.25%)
DOW   31,798.94 (-0.41%)
QQQ   285.53 (-0.60%)
AAPL   138.43 (-1.38%)
MSFT   258.50 (-0.43%)
FB   180.16 (-0.62%)
GOOGL   2,102.46 (-0.80%)
AMZN   2,071.00 (-0.53%)
TSLA   620.57 (-1.21%)
NVDA   159.72 (-1.13%)
BABA   83.16 (+0.84%)
AMD   90.38 (-0.86%)
MU   66.03 (-0.89%)
T   21.15 (-0.05%)
F   12.36 (-0.48%)
PFE   53.17 (-0.45%)
PYPL   77.92 (-0.93%)
NFLX   179.16 (-0.65%)
S&P 500   3,931.65 (-0.25%)
DOW   31,798.94 (-0.41%)
QQQ   285.53 (-0.60%)
AAPL   138.43 (-1.38%)
MSFT   258.50 (-0.43%)
FB   180.16 (-0.62%)
GOOGL   2,102.46 (-0.80%)
AMZN   2,071.00 (-0.53%)
TSLA   620.57 (-1.21%)
NVDA   159.72 (-1.13%)
BABA   83.16 (+0.84%)
AMD   90.38 (-0.86%)
MU   66.03 (-0.89%)
T   21.15 (-0.05%)
F   12.36 (-0.48%)
PFE   53.17 (-0.45%)
PYPL   77.92 (-0.93%)
NFLX   179.16 (-0.65%)
NASDAQ:MRTX

Mirati Therapeutics (MRTX) Stock Forecast, Price & News

$58.80
-4.78 (-7.52%)
(As of 05/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$58.30
$63.00
50-Day Range
$52.14
$88.71
52-Week Range
$51.16
$195.99
Volume
505,792 shs
Average Volume
727,653 shs
Market Capitalization
$3.26 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.61
30 days | 90 days | 365 days | Advanced Chart
Receive MRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Mirati Therapeutics logo

About Mirati Therapeutics

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRTX
Fax
N/A
Employees
413
Year Founded
N/A

Sales & Book Value

Annual Sales
$72.09 million
Book Value
$22.50 per share

Profitability

Net Income
$-581.78 million
Pretax Margin
-867.01%

Debt

Price-To-Earnings

Miscellaneous

Free Float
53,795,000
Market Cap
$3.26 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/04/2022
Today
5/25/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.96 out of 5 stars

Medical Sector

648th out of 1,420 stocks

Pharmaceutical Preparations Industry

305th out of 678 stocks

Analyst Opinion: 4.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -













Mirati Therapeutics (NASDAQ:MRTX) Frequently Asked Questions

Is Mirati Therapeutics a buy right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Mirati Therapeutics stock.
View analyst ratings for Mirati Therapeutics
or view top-rated stocks.

When is Mirati Therapeutics' next earnings date?

Mirati Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Mirati Therapeutics
.

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics, Inc. (NASDAQ:MRTX) announced its quarterly earnings data on Wednesday, May, 4th. The biotechnology company reported ($3.40) earnings per share for the quarter, missing the consensus estimate of ($3.37) by $0.03. The biotechnology company earned $0.71 million during the quarter, compared to analysts' expectations of $0.18 million. The firm's revenue for the quarter was up 6990.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($2.67) EPS.
View Mirati Therapeutics' earnings history
.

What price target have analysts set for MRTX?

12 analysts have issued 12-month price targets for Mirati Therapeutics' shares. Their forecasts range from $115.00 to $247.00. On average, they anticipate Mirati Therapeutics' stock price to reach $172.58 in the next twelve months. This suggests a possible upside of 193.5% from the stock's current price.
View analysts' price targets for Mirati Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Mirati Therapeutics' key executives?
Mirati Therapeutics' management team includes the following people:
  • Mr. David D. Meek, CEO & Director (Age 59, Pay $974.53k)
  • Dr. Charles M. Baum M.D., Ph.D., Founder, Pres, Head of R&D and Director (Age 64, Pay $1.11M) (LinkedIn Profile)
  • Ms. Vickie W. Reed, Sr. VP & Chief Accounting Officer (Age 60, Pay $570.7k) (LinkedIn Profile)
  • Dr. James G. Christensen Ph.D., Chief Scientific Officer (Age 54, Pay $784.42k)
  • Mr. Benjamin J. Hickey M.B.A., Chief Commercial Officer (Age 47, Pay $769.03k) (LinkedIn Profile)
  • Ms. Reena R. Desai, Chief Legal Officer & Corp. Sec.
  • Ms. Kristin Gustafson, Chief HR Officer
  • Dr. Kelly Covello Ph.D., VP & Head of Medical Affairs
  • Mr. Ryan Asay, VP & Head of Corp. Affairs
What other stocks do shareholders of Mirati Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Netflix (NFLX), Square (SQ), Alibaba Group (BABA) and DocuSign (DOCU).

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Who are Mirati Therapeutics' major shareholders?

Mirati Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.07%), BlackRock Inc. (5.04%), Wellington Management Group LLP (4.47%), State Street Corp (2.56%), Artal Group S.A. (2.43%) and RA Capital Management L.P. (1.32%). Company insiders that own Mirati Therapeutics stock include Benjamin Hickey, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Craig A Johnson, Daniel Faga, Henry J Fuchs, Jamie Christensen, Julie M Cherrington, Ltd Braslyn, Maria E Martinez and Vickie S Reed.
View institutional ownership trends for Mirati Therapeutics
.

Which major investors are selling Mirati Therapeutics stock?

MRTX stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Lord Abbett & CO. LLC, Paradigm Biocapital Advisors LP, Goldman Sachs Group Inc., Neuberger Berman Group LLC, Artal Group S.A., First Trust Advisors LP, and Royal Bank of Canada. Company insiders that have sold Mirati Therapeutics company stock in the last year include Benjamin Hickey, Charles M Baum, Jamie Christensen, Julie M Cherrington, and Vickie S Reed.
View insider buying and selling activity for Mirati Therapeutics
or view top insider-selling stocks.

Which major investors are buying Mirati Therapeutics stock?

MRTX stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, RA Capital Management L.P., Fiera Capital Corp, Bank of Montreal Can, Deerfield Management Company L.P. Series C, Eventide Asset Management LLC, Rock Springs Capital Management LP, and Suvretta Capital Management LLC.
View insider buying and selling activity for Mirati Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Mirati Therapeutics?

Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mirati Therapeutics' stock price today?

One share of MRTX stock can currently be purchased for approximately $58.80.

How much money does Mirati Therapeutics make?

Mirati Therapeutics has a market capitalization of $3.26 billion and generates $72.09 million in revenue each year. The biotechnology company earns $-581.78 million in net income (profit) each year or ($11.90) on an earnings per share basis.

How many employees does Mirati Therapeutics have?

Mirati Therapeutics employs 413 workers across the globe.

What is Mirati Therapeutics' official website?

The official website for Mirati Therapeutics is www.mirati.com.

How can I contact Mirati Therapeutics?

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at (858) 332-3410 or via email at [email protected].

This page was last updated on 5/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.